Posts by: Alice Melão

News

“Don’t Turn a Cold Shoulder to Painful Fingers” is the new campaign launched by the Raynaud’s Association to raise awareness about the pain experienced by those affected by Raynaud’s ... Read more

September 18, 2018September 18, 2018

Increased Skin Pigmentation Lesions May Help Predict Course of Systemic Sclerosis, Study Suggests

News

Evaluating changes in skin pigmentation could be useful for the management of systemic sclerosis (SSc) patients, particularly to identify those at risk of developing digital ulcers, researchers suggest. This ... Read more

September 11, 2018September 11, 2018

Acute Kidney Failure in Limited SSc Patient Reported in Rare Case Study

News

A case of acute renal crisis was reported in a patient with limited cutaneous systemic sclerosis (SSc) positive for anticentromere autoantibodies. This rare case was described in the study, ... Read more

September 6, 2018September 6, 2018

FDA Grants Fast Track Status to Fibrocell’s Gene Therapy FCX-013 for Localized Scleroderma

News

Fibrocell Science‘s gene therapy candidate FCX-013 received fast track designation by the U.S. Food and Drug Administration as a treatment for moderate-to-severe localized scleroderma, which usually does not affect internal ... Read more

September 4, 2018September 4, 2018

Skin High-frequency Ultrasound Can Be Used to Evaluate SSc Patients, Study Shows

News

High-frequency ultrasound (HFU) of the skin can help evaluate the progression and define disease activity in patients with systemic sclerosis (SSc), researchers suggest. This noninvasive method was seen to have ... Read more

July 5, 2018July 5, 2018

Cannabinoid-derived EHP-101 Eased Fibrosis in Systemic Sclerosis Mouse Model, Emerald Reports

News

Emerald Health Pharmaceuticals’ lead cannabinoid-derived treatment candidate, EHP-101, has shown potential to prevent skin and lung tissue scaring in a mouse model of systemic sclerosis, the company reports. Emerald also ... Read more

June 21, 2018June 21, 2018

Lenabasum Continues to Show Promise for Treatment of Systemic Sclerosis in Extension Study

News

Treatment with Corbus Pharmaceuticals’ investigative therapy lenabasum (formerly known as anabasum) significantly improves the symptoms of diffuse cutaneous systemic sclerosis in a Phase 2 open-label extension study. The latest results ... Read more

June 14, 2018June 14, 2018

85% of PAH, SSc-PAH Patients in Canada Now Have Publicly Funded Access to Uptravi

News

Approximately 85 percent of Canadians with pulmonary arterial hypertension (PAH) and systemic sclerosis (SSc) now have access to Actelion’s therapy Uptravi (selexipag) through the country’s publicly funded prescription system. ... Read more

May 17, 2018May 17, 2018

#EULAR2018 – Lenabasum Safe and Effective in Diffuse Scleroderma Patients, One-year Trial Data Show

News

Lenabasum, an investigational treatment of diffuse cutaneous systemic sclerosis by Corbus Pharmaceuticals, was shown to be safe, well-tolerated and of benefit to patients treated for one year in a long-term extension of a ... Read more

May 10, 2018May 10, 2018

Study Offers New Insights to Help Improve Diagnosis, Care of Juvenile Scleroderma Patients

News

Early diagnosis and prompt treatment was found to be critical in achieving better long-term outcomes for children with juvenile localized scleroderma, a study reports. The retrospective study, titled “Disease ... Read more

Posts by: Alice Melão

Alice Melão

Raynaud’s Association Campaign Aims to Raise Awareness About Disease’s Pain

Increased Skin Pigmentation Lesions May Help Predict Course of Systemic Sclerosis, Study Suggests

Acute Kidney Failure in Limited SSc Patient Reported in Rare Case Study

FDA Grants Fast Track Status to Fibrocell’s Gene Therapy FCX-013 for Localized Scleroderma

Skin High-frequency Ultrasound Can Be Used to Evaluate SSc Patients, Study Shows

Cannabinoid-derived EHP-101 Eased Fibrosis in Systemic Sclerosis Mouse Model, Emerald Reports

Lenabasum Continues to Show Promise for Treatment of Systemic Sclerosis in Extension Study

85% of PAH, SSc-PAH Patients in Canada Now Have Publicly Funded Access to Uptravi

#EULAR2018 – Lenabasum Safe and Effective in Diffuse Scleroderma Patients, One-year Trial Data Show

Study Offers New Insights to Help Improve Diagnosis, Care of Juvenile Scleroderma Patients

Pin It on Pinterest